Physician profile
Eric S Loos
NPI 1982396347
$1,276.33
in general payments reported to CMS, 2019-2025
34 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $240 · 2024: $474 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.36 |
| Education | $170.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $103.71 | 2023-2025 | |
| Seagen INC. | $98.87 | 2023-2025 | Tukysa |
| Biomarin Pharmaceutical INC. | $81.30 | 2024 | Roctavian |
| Novartis Pharmaceuticals Corporation | $78.62 | 2024-2025 | |
| Abbvie INC. | $76.13 | 2024-2025 | |
| Daiichi Sankyo INC. | $74.99 | 2024 | Enhertu |
| Genentech USA, INC. | $56.38 | 2024-2025 | Venclexta, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $51.83 | 2024-2025 | Enhertu, Tagrisso |
| Beone Medicines USA, INC. | $51.79 | 2025 | Tevimbra, Brukinsa |
| Karyopharm Therapeutics INC. | $49.58 | 2023-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $39.33 | 2025 | Lynozyfic |
| Celgene Corporation | $38.38 | 2023 | Reblozyl |
| Janssen Biotech, INC. | $33.85 | 2024-2025 | Rybrevant |
| Glaxosmithkline, LLC. | $33.68 | 2025 | Jemperli, Zejula |
| Incyte Corporation | $33.02 | 2023-2025 | Zynyz, Monjuvi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $30.70 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $29.72 | 2024-2025 | Reblozyl, Keytruda, Welireg |
| Array Biopharma INC | $24.92 | 2023 | Lorbrena, Braftovi, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $24.23 | 2023 | Opdivo |
| Servier Pharmaceuticals LLC | $23.08 | 2025 | |
| Iovance Biotherapeutics, INC. | $22.13 | 2025 | Amtagvi |
| Sobi, INC | $21.00 | 2024 | |
| Kite Pharma, INC. | $20.87 | 2024 | Yescarta |
| Astellas Pharma US INC | $19.93 | 2023 | Xospata |
| Ipsen Biopharmaceuticals, INC | $19.36 | 2024 | Onivyde |
| Rigel Pharmaceuticals, INC. | $17.32 | 2024 | Rezlidhia, Tavalisse |
| Eisai INC. | $17.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Caris Mpi, INC. | $15.69 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $15.61 | 2023 | Poteligeo |
| Geron Corporation | $15.53 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $14.25 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $13.65 | 2023 | Fotivda |
| Blueprint Medicines Corporation | $13.63 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Loos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.